Turing Pharmaceuticals AG to Testify at Congressional Hearing on Drug Pricing

Turing Pharmaceuticals AG today announced that Nancy Retzlaff, Chief Commercial Officer, will testify before a U.S. House Committee on Oversight and Government Reform hearing on drug pricing on Tuesday, January 26. Turing, a privately held biopharmaceutical company focused on commercializing and developing innovative treatments for rare and neglected diseases and conditions, produces Daraprim, a drug to treat Toxoplasmosis, an infection that can be life-threatening for certain people. Since fall 2015, Turing representatives have been in regular contact with staff to the House Committee on Oversight and Government reform, providing briefings and background material and answering questions. In testifying before the Committee, the company expects to detail the factors that See full press release